Skip to main content
. 2019 Sep 20;21(1):153–164. doi: 10.1007/s10198-019-01117-3

Table 3.

Base-case results of cost-effectiveness analyses

Comparison Costs (€) Costs 1st-line (€) LYs QALYs Δ Costs (€) Δ Effects ICER (€)
Gefitinib 65,889 39,467 2.01 1.36
Erlotinib 64,035 39,825 2.04 1.39 Dominates gefitinib
Afatinib 69,418 42,416 2.24 1.52 5383 0.13 41,504
Osimertinib 131,997 124,149 2.92 2.01 62,579 0.49 128,343

ICER incremental cost-effectiveness ratio, LYs life-years, QALYs quality-adjusted life-years, Δ difference in costs/effects